For help on how to get the results you want, see our search tips.
1997 results
-
List item
Human medicine European public assessment report (EPAR): Cinqaero (updated)
Reslizumab, Asthma
Date of authorisation: 15/08/2016, Revision: 11, Authorised, Last updated: 26/05/2023 -
List item
Human medicine European public assessment report (EPAR): Procysbi (updated)
mercaptamine bitartrate, Cystinosis
Date of authorisation: 05/09/2013,
, Revision: 16, Authorised, Last updated: 26/05/2023
-
List item
Human medicine European public assessment report (EPAR): Ogluo (updated)
Glucagon, Diabetes Mellitus
Date of authorisation: 11/02/2021, Revision: 5, Authorised, Last updated: 26/05/2023 -
List item
Human medicine European public assessment report (EPAR): Lyrica (updated)
pregabalin, Epilepsy; Anxiety Disorders; Neuralgia
Date of authorisation: 05/07/2004, Revision: 60, Authorised, Last updated: 26/05/2023 -
List item
Human medicine European public assessment report (EPAR): Xigduo (updated)
metformin hydrochloride, dapagliflozin propanediol monohydrate, Diabetes Mellitus, Type 2
Date of authorisation: 16/01/2014, Revision: 20, Authorised, Last updated: 26/05/2023 -
List item
Human medicine European public assessment report (EPAR): Beovu (updated)
brolucizumab, Wet Macular Degeneration
Date of authorisation: 13/02/2020,
, Revision: 8, Authorised, Last updated: 26/05/2023
-
List item
Human medicine European public assessment report (EPAR): Ixiaro (updated)
Japanese-encephalitis virus, inactivated (attenuated strain SA14-14-2 grown in vero cells), Encephalitis, Japanese; Immunization
Date of authorisation: 31/03/2009, Revision: 17, Authorised, Last updated: 25/05/2023 -
List item
Human medicine European public assessment report (EPAR): Breyanzi (updated)
CD19-directed genetically modified autologous cell-based product consisting of purified CD8+ T-cells (CD8+ cells), CD19-directed genetically modified autologous cell-based product consisting of purified CD4+ T cells (CD4+ cells), Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Mediastinal Neoplasms
Date of authorisation: 04/04/2022,, Revision: 1, Authorised, Last updated: 25/05/2023
-
List item
Human medicine European public assessment report (EPAR): Livmarli (updated)
Maralixibat chloride, Alagille Syndrome
Date of authorisation: 09/12/2022,, , 
, Revision: 1, Authorised, Last updated: 25/05/2023
-
List item
Human medicine European public assessment report (EPAR): Galafold (updated)
Migalastat hydrochloride, Fabry Disease
Date of authorisation: 25/05/2016,, , Revision: 16, Authorised, Last updated: 25/05/2023
-
List item
Human medicine European public assessment report (EPAR): Xaluprine (previously Mercaptopurine Nova Laboratories) (updated)
6-mercaptopurine monohydrate, Leukemia, Lymphoid
Date of authorisation: 09/03/2012, Revision: 15, Authorised, Last updated: 25/05/2023 -
List item
Human medicine European public assessment report (EPAR): Sustiva (updated)
efavirenz, HIV Infections
Date of authorisation: 28/05/1999, Revision: 48, Authorised, Last updated: 25/05/2023 -
List item
Human medicine European public assessment report (EPAR): Dupixent (updated)
dupilumab, Dermatitis, Atopic; Prurigo; Esophageal Diseases; Asthma; Sinusitis
Date of authorisation: 26/09/2017, Revision: 26, Authorised, Last updated: 25/05/2023 -
List item
Human medicine European public assessment report (EPAR): Pantozol Control (updated)
pantoprazole, Gastroesophageal Reflux
Date of authorisation: 11/06/2009, Revision: 17, Authorised, Last updated: 25/05/2023 -
List item
Human medicine European public assessment report (EPAR): Olumiant (updated)
Baricitinib, Arthritis, Rheumatoid
Date of authorisation: 13/02/2017,
, Revision: 13, Authorised, Last updated: 25/05/2023
-
List item
Human medicine European public assessment report (EPAR): Lixiana (updated)
edoxaban tosilate, Stroke; Venous Thromboembolism
Date of authorisation: 19/06/2015, Revision: 16, Authorised, Last updated: 25/05/2023 -
List item
Human medicine European public assessment report (EPAR): Elfabrio (updated)
Pegunigalsidase alfa, Fabry Disease
Date of authorisation: 04/05/2023, Revision: 1, Authorised, Last updated: 25/05/2023 -
List item
Human medicine European public assessment report (EPAR): Tenkasi (previously Orbactiv) (updated)
oritavancin diphosphate, Soft Tissue Infections; Skin Diseases, Bacterial
Date of authorisation: 19/03/2015, Revision: 12, Authorised, Last updated: 25/05/2023 -
List item
Human medicine European public assessment report (EPAR): Orkambi (updated)
Lumacaftor, ivacaftor, Cystic Fibrosis
Date of authorisation: 18/11/2015, Revision: 31, Authorised, Last updated: 25/05/2023 -
List item
Human medicine European public assessment report (EPAR): Trisenox (updated)
Arsenic trioxide, Leukemia, Promyelocytic, Acute
Date of authorisation: 05/03/2002, Revision: 31, Authorised, Last updated: 25/05/2023 -
List item
Human medicine European public assessment report (EPAR): Fasenra (updated)
Benralizumab, Asthma
Date of authorisation: 08/01/2018, Revision: 10, Authorised, Last updated: 25/05/2023 -
List item
Human medicine European public assessment report (EPAR): Evoltra (updated)
clofarabine, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Date of authorisation: 29/05/2006,, , Revision: 33, Authorised, Last updated: 25/05/2023
-
List item
Human medicine European public assessment report (EPAR): Nexviadyme (updated)
Avalglucosidase alfa, Glycogen Storage Disease Type II
Date of authorisation: 24/06/2022,, Revision: 2, Authorised, Last updated: 25/05/2023
-
List item
Human medicine European public assessment report (EPAR): Lopinavir/Ritonavir Mylan (updated)
lopinavir, ritonavir, HIV Infections
Date of authorisation: 14/01/2016,
, Revision: 16, Authorised, Last updated: 25/05/2023
-
List item
Human medicine European public assessment report (EPAR): Controloc Control (updated)
pantoprazole, Gastroesophageal Reflux
Date of authorisation: 11/06/2009, Revision: 15, Authorised, Last updated: 25/05/2023